Impact of Human Papillomavirus Vaccination in Reducing Cancer.

Human papillomavirus (HPV) is a significant cause of global morbidity and mortality. A nonavalent HPV vaccine is widely available and recommended for routine use at 11 to 12 years old. Older teens and adults though age 45 years also could be offered vaccination. Widespread use of the HPV vaccine appears to impact the rate of infections and cancers. Some parents/teens may hesitate to be vaccinated. The strongest predictor to receiving the vaccine remains a trusted health care professional making a strong recommendation to receive the vaccine. New HPV vaccines are in the pipeline, including therapeutic vaccines to treat HPV-related cancers.
Competing Interests: Disclosure The authors have nothing to disclose.
(Copyright © 2020 Elsevier Inc. All rights reserved.)